First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer

Conclusion: 177Lu-rhPSMA-10.1 demonstrated encouraging preliminary efficacy and was well tolerated. Formal clinical trials are now under way to evaluate its potential prospectively (NCT05413850).

Source: Journal of Nuclear Medicine - March 1, 2024 Category: Nuclear Medicine Authors: Dierks, A., Gable, A., Rinscheid, A., Wienand, G., Pfob, C. H., Kircher, M., Enke, J. S., Janzen, T., Patt, M., Trepel, M., Weckermann, D., Bundschuh, R. A., Lapa, C. Tags: Clinical Investigations Source Type: research